Novo Sees Ozempic Boom Prompting Another Sales Surge

Novo Nordisk A/S expects sales to surge again this year as the Danish drugmaker builds supply for blockbuster diabetes medicine Ozempic and obesity treatment Wegovy.
Revenue will likely grow by 16% to 24% at constant exchange rates, compared with 26% for last year.
The company predicts operating profit growth as high as 27% at constant currencies this year. Bloomberg Madison Muller reports on Bloomberg Intelligence
--------
Get more on The Bloomberg Intelligence Podcast
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:

Visit our YouTube channels:

[michaelclanton]

Novo needs a direct buy in the USA to compete with the Lilly direct buy and bypass the PBM'S

[AliAhmad-grhk]

And yet Lilly barely make earnings and stock already 20% up. It’s all BS.

[jacobflores]

RFK is going to shut that down ASAP!!!! Bio Sell Off coming in hot!!!!